Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims do not align with the provided FDA label excerpts for Aspirin and Extended-Release Dipyridamole Capsules (e.g., indication is stroke/TIA; dosing is 1 capsule twice daily; label does not support 325 mg OTC-like frequency/dose guidance). Several safety statements about patient-specific risk factors and contraindication use-cases are not supported by the supplied label text.
Category Scores
Accurate Statements
Taking aspirin and extended-release dipyridamole increases the risk of bleeding.
Label 5.1: "Aspirin and extended-release dipyridamole increases the risk of bleeding."
Taking aspirin and extended-release dipyridamole more often than label allows can increase bleeding risk.
Supported only in principle by Label 5.1 stating increased bleeding risk with this product; however the label excerpts provided do not state frequency-based limits for 325 mg aspirin, so support is indirect.
Unsupported Statements
There is not a single universal maximum frequency for 325 mg aspirin because it depends on the indication and patient health risks.
No label excerpt provides any universal maximum frequency for 325 mg aspirin or frequency limits by indication/patient risks.
For short-term pain or fever in adults, aspirin is often taken every 4 to 6 hours as needed.
Provided label excerpt is for stroke risk reduction in TIA/completed ischemic stroke; no pain/fever dosing/frequency is included.
For short-term pain or fever in adults, the maximum daily dose stated on the product label should not be exceeded.
Label excerpt provided does not include any daily maximum dose guidance for pain/fever, nor does it reference 325 mg aspirin dosing maxima.
For daily heart-related prevention, a common “low-dose” is 81 mg.
No label excerpt states a 81 mg low-dose for heart prevention; label indication is stroke risk reduction in TIA/stroke patients.
People generally don’t use 325 mg aspirin daily for heart prevention unless a clinician specifically directs it.
No label excerpt addresses 325 mg aspirin use patterns or general practice statements.
Even when using a fixed dose of 325 mg each time, frequency is capped by the total maximum daily dose allowed for that indication.
No label excerpt provides frequency or maximum daily dose constraints for 325 mg aspirin by indication.
Taking 325 mg aspirin more often than the label allows can increase the risk of stomach irritation.
Label includes GI side effects and advises avoiding active peptic ulcer disease, but the specific claim about "stomach irritation" tied to exceeding a 325 mg frequency/label limit is not supported by the provided excerpts.
The safer upper limit for aspirin frequency varies based on other medicines, especially blood thinners, antiplatelets, or NSAIDs.
Label 5.1 supports increased bleeding risk with concomitant anticoagulants/antiplatelets/chronic NSAIDs, but it does not provide frequency upper limits or dosing-limit guidance framed as an "upper limit for aspirin frequency".
The safer upper limit for aspirin frequency varies based on a history of stomach ulcers or GI bleeding.
Label 5.1 says avoid using aspirin in patients with history of active peptic ulcer disease; it does not provide frequency upper limits based on history of ulcers/GI bleeding.
The safer upper limit for aspirin frequency varies based on kidney disease.
Label 5.2 advises avoid aspirin in severe renal failure (GFR <10), but does not provide frequency upper limits.
The safer upper limit for aspirin frequency varies based on liver disease.
Label 5.3 discusses hepatic enzyme elevations and hepatic failure; and 8.6 advises avoid aspirin-containing products in severe hepatic dysfunction, but no frequency upper limits are stated.
The safer upper limit for aspirin frequency varies based on uncontrolled high blood pressure.
No provided label excerpt mentions high blood pressure as a factor affecting aspirin frequency limits.
Older adults have higher GI bleeding risk with aspirin.
No provided label excerpt states older adults have higher GI bleeding risk.
The safer upper limit for aspirin frequency varies based on whether it is used for fever/pain versus cardiovascular prevention.
Label excerpt provided is not for fever/pain indications; it also does not provide any frequency limit framework.
Do not use aspirin for pain/fever without medical guidance if there is a history of stomach ulcers or GI bleeding.
Label 5.1 says avoid using aspirin in patients with a history of active peptic ulcer disease; it does not address pain/fever OTC use or GI bleeding generally in the phrasing given.
Do not use aspirin for pain/fever without medical guidance if there are bleeding disorders or if the patient takes anticoagulants.
Label 5.1 supports increased bleeding risk with anticoagulants/antiplatelet agents, but it does not state a blanket instruction "do not use aspirin for pain/fever" for bleeding disorders.
Do not use aspirin for pain/fever without medical guidance if there is aspirin allergy or aspirin-triggered asthma.
Label 4.2 contains contraindications for aspirin allergy and asthma/rhinitis/nasal polyps. However, the claim is framed as OTC pain/fever use without medical guidance, which is not present in the provided label excerpts.
Do not use aspirin for pain/fever without medical guidance if there is active significant illness where bleeding risk is high.
No provided label excerpt supports this generalized statement.
For children/teens, aspirin is generally avoided due to Reye’s syndrome risk unless specifically directed by a clinician.
Label 4.3 says "Do not use aspirin in children or teenagers with viral infections because of the risk of Reye syndrome." The AI claim is broader/general and not limited to viral infections as in the label excerpt.
If someone already took multiple 325 mg doses, they should stop taking additional aspirin until they can confirm the maximum daily dose on the specific product label.
No label excerpt provides instructions for stopping after taking multiple 325 mg doses or an actionable "maximum daily dose" for 325 mg aspirin in this context.
After taking multiple 325 mg doses, contacting a pharmacist or clinician for dosing guidance is advised, especially if stomach pain/black stools, unusual bruising, or vomiting blood occurs.
Label excerpt instructs to inform patients about signs/symptoms of GI side effects and bleeding, but it does not provide guidance for overdose-like situations described as taking multiple 325 mg doses, nor does it specifically recommend contacting pharmacist/clinician under those circumstances.
Contradictions
Low
AI Statement
For daily heart-related prevention, a common “low-dose” is 81 mg.
Label Reference
Provided label indication and dosing in the excerpts do not mention 81 mg for heart prevention; therefore this conflicts with the label excerpt context (stroke prevention indication), though no direct numeric contradiction is stated.
Important Omissions
The FDA label excerpt indicates the product is indicated to reduce risk of stroke in patients with transient ischemia of the brain or completed ischemic stroke due to thrombosis.
Importance:
Moderate
The FDA label excerpt gives the recommended dose as one capsule orally twice daily (morning and evening) and instructs to swallow capsules whole without chewing; it also states the product is not interchangeable with individual components.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several claims provide dosing/frequency guidance for 325 mg aspirin in pain/fever and heart prevention, which is not supported by the provided label excerpts for this specific prescription product. While the label supports increased bleeding risk and key contraindications (aspirin hypersensitivity/NSAID allergy/asthma syndrome/viral infection pediatric Reye syndrome), the specific frequency/upper-limit narratives for 325 mg are largely unsupported and could mislead dosing decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Claims heavily rely on 325 mg aspirin pain/fever and heart-prevention frequency/dose conventions that are not present in the supplied FDA label excerpts for Aspirin and Extended-Release Dipyridamole Capsules.
Suggested Improvement
Reframe content to match the provided label: stroke/TIA indication; recommended dose is 1 capsule twice daily; emphasize label-supported contraindications (hypersensitivity, NSAID allergy/asthma syndrome, avoid in children/teens with viral infections) and label-supported precautions (increased bleeding risk especially with anticoagulants/antiplatelets/chronic NSAIDs; avoid in severe renal failure; avoid in history of active peptic ulcer disease). Avoid stating unsupported 325 mg maximum frequencies or OTC-like pain/fever dosing intervals.